VivoSeq
Oncology

Cutaneous Squamous Cell Carcinoma

42

Pipeline Programs↗

16

Active Trials↗

19

Companies Involved↗

Cutaneous Squamous Cell Carcinoma is a moderately active landscape with 42 programs across 19 companies. The most active players are Turnstone Biologics, Corp., Novartis, Ankyra Therapeutics, Inc. 1 therapy is approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

59/100

Pipeline Velocity

15/100

Mech. Concentration

13/100

Completion Rate

54/100

Attrition Rate

24/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

T

Turnstone Biologics, Corp.

2 programs

Phase 1Novartis logo

Novartis

1 program

Phase 1A

Ankyra Therapeutics, Inc

1 program

Phase 1AstraZeneca logo

AstraZeneca

1 program

Phase 1Bristol-Myers Squibb logo

Bristol-Myers Squibb

3 programs

Phase 2Incyte logo

Incyte

2 programs

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

61%

Small molecule

23 of 38 classified programs — the dominant modality here.

39%ALL OTHERSMonoclonal antibody1334%Antibody–drug conjugate13%Peptide13%

Small molecule leads; the ring shows all 38 classified programs, each share of the total. Modality classified for 98% of 42 pipeline programs.

Analysis

Trial Status

46

clinical trials

Completed13 · 28%
Recruiting7 · 15%
Withdrawn7 · 15%
Active, not recruiting6 · 13%
Unknown status5 · 11%
Terminated4 · 9%
Other4 · 9%

Clinical Trials

Trial Activity

46 trials

A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision
Recruiting·—·Phase 1·NCT06664151·25 enrolled
B-catenin in Cutaneous Squamous Cell Carcinoma and Its Mimickers
Recruiting·SSohag University·N/A·NCT06536946·50 enrolled
Phase 2 Pragmatic Trial of Sentinel Lymph Node Biopsy (SLNB) in Patients With Clinically Node-Negative (cN0), High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) of the Head and Neck
Recruiting·UUniversity of California, Davis·Phase 2·NCT06990737·24 enrolled
Neoadjuvant Pembrolizumab in Cutaneous Squamous Cell Carcinoma
Recruiting·QQueensland Health·Phase 2·NCT05025813·27 enrolled
Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma
Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06567314·24 enrolled
Pembrolizumab for the Treatment of Locally Advanced and/or Recurrent Orbital or Periocular Cutaneous Squamous Cell Carcinoma
Recruiting·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT06580054·22 enrolled
A Phase 2, Open Label, Single Arm, Clinical Trial of Neoadjuvant Nivolumab and Relatlimab in Stage II To IV (M0) Resectable Cutaneous Squamous Cell Carcinoma
Recruiting·MMelanoma Institute Australia·Phase 2·NCT06288191·20 enrolled
A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)
Active, not recruiting·Merck & Co. logoMerck & Co.·Phase 2/3·NCT06295809·46 enrolled
Neoadjuvant Study of PD-1 Inhibitor Pembrolizumab in PD-1 Naive Cutaneous Squamous Cell Carcinoma (cSCC)
Active, not recruiting·—·Phase 2·NCT04808999·30 enrolled
A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma
Active, not recruiting·Incyte logoIncyte·Phase 2·NCT05888844·63 enrolled
Deep sequencIng in Cutaneous Squamous CEll caRciNomas
Active, not recruiting·PPeter MacCallum Cancer Centre, Australia·Phase 2·NCT05878288·11 enrolled
Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma
Active, not recruiting·Regeneron logoRegeneron·Phase 3·NCT03969004·415 enrolled
A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)
Active, not recruiting·Merck & Co. logoMerck & Co.·Phase 2·NCT06041802·19 enrolled
Pucotenlimab Combined With Becotatug Vedotin in Advanced Cutaneous Squamous Cell Carcinoma
Not yet recruiting·FFudan University·Phase 2·NCT07394244·38 enrolled
Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma
Not yet recruiting·MMelanoma and Skin Cancer Trials Limited·Phase 2·NCT06418724·27 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)